Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea
- PMID: 32585855
- PMCID: PMC7355553
- DOI: 10.3390/jcm9061959
Clinical Characteristics and Disease Progression in Early-Stage COVID-19 Patients in South Korea
Abstract
A rapid increase in the number of patients with coronavirus disease 19 (COVID-19) may overwhelm the available medical resources. We aimed to evaluate risk factors for disease severity in the early stages of COVID-19. The cohort comprised 293 patients with COVID-19 from 5 March 2020, to 18 March 2020. The Korea Centers for Disease Control and Prevention (KCDC) classification system was used to triage patients. The clinical course was summarized, including the impact of drugs (angiotensin II receptor blockers [ARB], ibuprofen, and dipeptidyl peptidase-4 inhibitors [DPP4i]) and the therapeutic effect of lopinavir/ritonavir. After adjusting for confounding variables, prior history of drug use, including ARB, ibuprofen, and DPP4i was not a risk factor associated with disease progression. Patients treated with lopinavir/ritonavir had significantly shorter progression-free survival than those not receiving lopinavir/ritonavir. KCDC classification I clearly distinguished the improvement/stabilization group from the progression group of COVID-19 patients (AUC 0.817; 95% CI, 0.740-0.895).
Keywords: Korea centers for disease control and prevention (KCDC) classification; angiotensin II receptor blockers (ARB); coronavirus disease-19 (COVID-19); ibuprofen; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Conflict of interest statement
The authors declare no conflicts of interest.
Figures


Similar articles
-
Lessons from South Korea Regarding the Early Stage of the COVID-19 Outbreak.Healthcare (Basel). 2020 Jul 24;8(3):229. doi: 10.3390/healthcare8030229. Healthcare (Basel). 2020. PMID: 32722174 Free PMC article.
-
Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir.Front Med (Lausanne). 2020 May 19;7:241. doi: 10.3389/fmed.2020.00241. eCollection 2020. Front Med (Lausanne). 2020. PMID: 32574332 Free PMC article.
-
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.Thorax. 2004 Mar;59(3):252-6. doi: 10.1136/thorax.2003.012658. Thorax. 2004. PMID: 14985565 Free PMC article. Clinical Trial.
-
DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?Front Pharmacol. 2020 Aug 7;11:1161. doi: 10.3389/fphar.2020.01161. eCollection 2020. Front Pharmacol. 2020. PMID: 32848769 Free PMC article. Review.
-
Effect of the establishment of the Korea Centers for Disease Control and Prevention/Korea Disease Control and Prevention Agency from the perspective of global health security.Glob Health Med. 2025 Apr 30;7(2):141-150. doi: 10.35772/ghm.2025.01015. Glob Health Med. 2025. PMID: 40321451 Free PMC article. Review.
Cited by
-
COVID-19 Triage and Test Center: Safety, Feasibility, and Outcomes of Low-Threshold Testing.J Clin Med. 2020 Oct 7;9(10):3217. doi: 10.3390/jcm9103217. J Clin Med. 2020. PMID: 33036445 Free PMC article.
-
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.Lancet Infect Dis. 2023 Jan;23(1):e22-e33. doi: 10.1016/S1473-3099(22)00433-9. Epub 2022 Aug 26. Lancet Infect Dis. 2023. PMID: 36030796 Free PMC article. Review.
-
Precautionary Behavior Practices and Psychological Characteristics of COVID-19 Patients and Quarantined Persons.Int J Environ Res Public Health. 2021 Jun 4;18(11):6070. doi: 10.3390/ijerph18116070. Int J Environ Res Public Health. 2021. PMID: 34199908 Free PMC article.
-
SARS-CoV-2 infection and multi-organ system damage: A review.Biomol Biomed. 2023 Feb 1;23(1):37-52. doi: 10.17305/bjbms.2022.7762. Biomol Biomed. 2023. PMID: 36124445 Free PMC article. Review.
-
Policy Review and Modeling Analysis of Mitigation Measures for Coronavirus Disease Epidemic Control, Health System, and Disease Burden, South Korea.Emerg Infect Dis. 2021 Nov;27(11):2753-2760. doi: 10.3201/eid2711.203779. Epub 2021 Aug 24. Emerg Infect Dis. 2021. PMID: 34429188 Free PMC article. Review.
References
-
- Richman D.D., Whitley R.J., Hayden F.G. Clinical Virology. 4th ed. ASM Press; Washington, DC, USA: 2016.
-
- Hui D.S., Azhar I.E., Madani T.A., Ntoumi F., Kock R., Dar O., Ippolito G., McHugh T.D., Memish Z.A., Drosten C., et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 2020;91:264–266. doi: 10.1016/j.ijid.2020.01.009. - DOI - PMC - PubMed
-
- Coronavirus Disease (COVID-2019) Situation Reports. World Health Organization (WHO); Geneva, Switzerland: 2020.
LinkOut - more resources
Full Text Sources
Miscellaneous